MENLO PARK, Calif.–(BUSINESS WIRE)–Today xCella Biosciences announced a new antibody discovery research
collaboration with Teva Pharmaceuticals Australia Pty Ltd. xCella will
use its xPlorationTM single cell screening platform to
identify rare antibodies against an undisclosed target of interest to
Teva.
“Our xPloration platform offers new technology for high-throughput B
cell screening to enable antibody discovery against complex membrane
protein targets. We look forward to working closely with Teva, a leading
global company, to help them achieve their drug discovery goals.” said
Dr. Jennifer Cochran, Co-Founder and Executive Chairman of xCella.
“Teva is excited to utilize xCella’s xPloration platform and
expertise to identify unique antibodies against our therapeutic
targets,” said Dr. Steffen Nock, Senior Vice President, Global Specialty
R&D at Teva.
Under the terms of this agreement, xCella Biosciences will receive
certain payments based on the development and commercialization of
therapeutic antibodies for up to four disease targets. Specific
financial terms of the agreement have not been disclosed.
About xCella Biosciences
xCella is an antibody engineering and drug discovery company based on
intellectual property originally developed at Stanford University in the
Stanford Photonics Research Center and the laboratory of Dr. Jennifer
Cochran in the Stanford Department of Bioengineering. The xPlorationTM
platform enables high throughput screening of millions of B cells based
on cell binding or functional activity, presenting distinctive
opportunities for the creation of novel therapeutics. In addition to its
internal drug discovery and development programs, xCella has entered
into partnership agreements with leading pharmaceutical and
biotechnology companies to develop best in-class protein-based assets in
key strategic areas of interest.
About Teva
Teva Pharmaceutical Industries Ltd. has been developing and producing
medicines to improve people’s lives for more than a century. We are a
global leader in generic and specialty medicines with a portfolio
consisting of over 35,000 products in nearly every therapeutic area.
Around 200 million people around the world take a Teva medicine every
day, and are served by one of the largest and most complex supply chains
in the pharmaceutical industry. Along with our established presence in
generics, we have significant innovative research and operations
supporting our growing portfolio of specialty and biopharmaceutical
products. Learn more at www.tevapharm.com
For more about xCella, please visit www.xcellabio.com
or email info@xcellabio.com.
Contacts
xCella Biosciences, Inc.
Jennifer Cochran, PhD
Co-founder and
Executive Chairman
info@xcellabio.com